Search

Your search keyword '"Papenburg J"' showing total 184 results

Search Constraints

Start Over You searched for: Author "Papenburg J" Remove constraint Author: "Papenburg J"
184 results on '"Papenburg J"'

Search Results

1. Clinical Presentations and Outcomes of Children in Canada With Recurrent Invasive Pneumococcal Disease From the IMPACT Surveillance Network

2. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: a systematic review and meta-analysis of standardized population-based studies

3. A second update on mapping the human genetic architecture of COVID-19

5. Seroprevalence of anti-SARS-CoV-2 antibodies among school and daycare children and personnel: Protocol for a cohort study in Montreal, Canada

10. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series

11. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series

12. A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs

15. Do Productivity Costs Matter?

21. Seroconversion to seasonal influenza viruses after A(H1N1)pdm09 virus infection, Quebec, Canada.

22. Panton-Valentine leukocidin in pediatric community-acquired Staphylococcus aureus infections.

23. Pediatric injuries from needles discarded in the community: epidemiology and risk of seroconversion.

24. Next-generation rapid phenotypic antimicrobial susceptibility testing.

25. Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2024-2025.

26. Summary of the National Advisory Committee on Immunization (NACI) Supplemental Guidance on Influenza Vaccination in Adults 65 Years of Age and Older.

27. Parental decisions regarding the vaccination of children and adolescents against SARS-CoV-2 from 2020 to 2023: A descriptive longitudinal study of parents and children in Montreal, Canada.

28. Nirsevimab-a breakthrough in respiratory syncytial virus bronchiolitis.

29. Whole-of-Life Inclusion in Bayesian Adaptive Platform Clinical Trials.

30. Omicron incidence and seroprevalence among children in Montreal, Canada, in early 2023: final results from the longitudinal EnCORE serology study.

32. SARS-CoV-2 seroprevalence and mental health of school staff: a cross-sectional study of schools from four areas of Montreal, Quebec in 2021.

33. Mental Health Hospitalizations in Canadian Children, Adolescents, and Young Adults Over the COVID-19 Pandemic.

34. Characteristics associated with SARS-CoV-2 testing, infection and vaccine uptake among essential non-healthcare workers in Montréal, 2021.

35. Antibiotic use in children hospitalised for influenza, 2010-2021: the Canadian Immunization Monitoring Program Active (IMPACT).

36. Clinical Outcomes of Rapid Respiratory Virus Testing in Emergency Departments: A Systematic Review and Meta-Analysis.

37. Summary of the National Advisory Committee on Immunization (NACI) Updated Guidance on Influenza Vaccination During Pregnancy.

38. The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus.

39. Bloodstream Infections in Children Hospitalized for Influenza, the Canadian Immunization Monitoring Program Active.

40. Neurological involvement in hospitalized children with SARS-CoV-2 infection: a multinational study.

41. Two-phase Bayesian latent class analysis to assess diagnostic test performance in the absence of a gold standard: COVID-19 serological assays as a proof of concept.

42. The rapidly changing landscape of respiratory syncytial virus prophylaxis.

44. Paediatric inflammatory multisystem syndrome in Canada: population-based surveillance and role of SARS-CoV-2 linkage.

45. Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic.

46. Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2023-2024.

47. The effect of Telehealth Antimicrobial Stewardship Program (Tele-ASP) on antimicrobial use in a pediatric intensive care unit: Pre- and post-implementation single center study.

48. In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections.

49. Infection-induced seroconversion and seroprevalence of SARS-CoV-2 among a cohort of children and youth in Montreal, Canada.

50. Outcomes of immunocompromised children hospitalized for Influenza, 2010-2021, the Canadian Immunization Monitoring Program Active (IMPACT).

Catalog

Books, media, physical & digital resources